TAS2R63P

Across TCGA pan-cancer cohorts, TAS2R63P RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TAS2R63P’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where TAS2R63P RNA is repressed in tumor relative to normal tissue. In most cancer types TAS2R63P is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

THCA, CHOL, and ESCA are the cancer types where TAS2R63P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TAS2R63P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.235	<.001	8	view →
CHOL	All	II,III,IV	+0.395	<.001	3	view →
ESCA	All	II,III,IV	+0.130	.002	2	view →
KIRP	All	II,III,IV	+0.055	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TAS2R63P–THCA

Open the THCA breakdown →